Cogent Biosciences, Inc. Proceeds from Sale and Maturity of Marketable Securities
Cogent Biosciences, Inc. (COGT) reported Proceeds from Sale and Maturity of Marketable Securities of $195.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-10
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $97.46M, a 26.69% increase year-over-year.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $97.83M, a 39.91% increase year-over-year.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $73.26M, a 1.62% decline year-over-year.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $69.08M, a 13.57% decline year-over-year.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $289.20M, a 1.78% decline from fiscal 2024.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $294.45M, a 16.03% increase from fiscal 2023.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $253.78M, a 322.96% increase from fiscal 2022.
- Cogent Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $60.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $97.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $195.29M 10-Q · filed 2026-08-10 | $268.55M derived: sum of 3 quarters · filed 2026-08-10 | $337.64M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $97.83M 10-Q · filed 2026-05-05 | $171.09M derived: sum of 2 quarters · filed 2026-05-05 | $240.18M derived: sum of 3 quarters · filed 2026-05-05 | $317.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $73.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $142.35M derived: sum of 2 quarters · filed 2026-02-17 | $219.27M derived: sum of 3 quarters · filed 2026-08-10 | $289.20M 10-K · filed 2026-02-17 |
| 2025-09-30 | $69.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $146.01M derived: sum of 2 quarters · filed 2026-08-10 | $215.94M 10-Q · filed 2025-11-07 | $290.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $76.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $146.85M 10-Q · filed 2026-08-10 | $221.32M derived: sum of 3 quarters · filed 2026-08-10 | $301.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $69.93M 10-Q · filed 2026-05-05 | $144.40M derived: sum of 2 quarters · filed 2026-05-05 | $224.33M derived: sum of 3 quarters · filed 2026-05-05 | $290.25M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $74.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $154.40M derived: sum of 2 quarters · filed 2026-02-17 | $220.32M derived: sum of 3 quarters · filed 2026-02-17 | $294.45M 10-K · filed 2026-02-17 |
| 2024-09-30 | $79.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $145.85M derived: sum of 2 quarters · filed 2025-11-07 | $219.98M 10-Q · filed 2025-11-07 | $281.70M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $65.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $140.05M 10-Q · filed 2025-08-05 | $201.77M derived: sum of 3 quarters · filed 2026-02-17 | $223.82M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $74.13M 10-Q · filed 2025-05-06 | $135.85M derived: sum of 2 quarters · filed 2026-02-17 | $157.90M derived: sum of 3 quarters · filed 2026-02-17 | $207.90M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $61.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $83.78M derived: sum of 2 quarters · filed 2026-02-17 | $133.78M derived: sum of 3 quarters · filed 2026-02-17 | $253.78M 10-K · filed 2026-02-17 |
| 2023-09-30 | $22.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $72.06M derived: sum of 2 quarters · filed 2024-11-12 | $192.06M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $170.00M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $120.00M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $60.00M 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $8.00M derived: sum of 3 quarters · filed 2021-03-16 | $22.99M 10-K · filed 2021-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $8.00M derived: sum of 2 quarters · filed 2020-11-09 | $22.99M 10-Q · filed 2020-11-09 | $37.99M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $22.99M 10-Q · filed 2020-08-11 | $37.99M derived: sum of 3 quarters · filed 2020-08-11 | $47.99M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $14.99M 10-Q · filed 2020-05-11 | $29.99M derived: sum of 2 quarters · filed 2020-05-11 | $39.99M derived: sum of 3 quarters · filed 2020-05-11 | $46.69M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $25.00M derived: sum of 2 quarters · filed 2020-03-26 | $31.70M derived: sum of 3 quarters · filed 2020-03-26 | $37.70M 10-K · filed 2020-03-26 |
| 2018-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $16.70M derived: sum of 2 quarters · filed 2019-11-12 | $22.70M 10-Q · filed 2019-11-12 | $27.70M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $6.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $12.70M 10-Q · filed 2019-08-12 | $17.70M derived: sum of 3 quarters · filed 2019-08-12 | $23.70M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $6.00M 10-Q · filed 2019-05-13 | $11.00M derived: sum of 2 quarters · filed 2019-05-13 | $17.00M derived: sum of 3 quarters · filed 2019-05-13 | $23.00M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $11.00M derived: sum of 2 quarters · filed 2019-03-28 | $17.00M derived: sum of 3 quarters · filed 2019-03-28 | $21.00M 10-K · filed 2019-03-28 |
| 2017-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $12.00M derived: sum of 2 quarters · filed 2018-11-13 | $16.00M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $10.00M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $4.00M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |